These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 25404020)

  • 61. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
    Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC
    N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Principles for designing future regimens for multidrug-resistant tuberculosis.
    Brigden G; Nyang'wa BT; du Cros P; Varaine F; Hughes J; Rich M; Horsburgh CR; Mitnick CD; Nuermberger E; McIlleron H; Phillips PP; Balasegaram M
    Bull World Health Organ; 2014 Jan; 92(1):68-74. PubMed ID: 24391302
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
    Stinson K; Kurepina N; Venter A; Fujiwara M; Kawasaki M; Timm J; Shashkina E; Kreiswirth BN; Liu Y; Matsumoto M; Geiter L
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3316-22. PubMed ID: 26976868
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
    Hwang H; Kang H; Kwon YS; Jeon D; Shim TS; Yim JJ
    Clin Infect Dis; 2021 Oct; 73(8):1362-1369. PubMed ID: 33837767
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
    Olayanju O; Esmail A; Limberis J; Dheda K
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31619478
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs.
    Sullivan T; Ben Amor Y
    Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26889711
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.
    Dawson R; Diacon AH; Takuva S; Liu Y; Zheng B; Karwe V; Hafkin J
    Trials; 2024 Jan; 25(1):70. PubMed ID: 38243296
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An Experience with Delamanid in an XDR TB Case - Case Report.
    Mohan N; Kaur M; Singhal L; Saini V; Chander J
    Infect Disord Drug Targets; 2021; 21(4):637-639. PubMed ID: 32691718
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Delamanid Resistance: Update and Clinical Management.
    Nguyen TVA; Anthony RM; Cao TTH; Bañuls AL; Nguyen VAT; Vu DH; Nguyen NV; Alffenaar JC
    Clin Infect Dis; 2020 Dec; 71(12):3252-3259. PubMed ID: 32521000
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.
    Mukherjee A; Lodha R; Kabra SK
    Expert Opin Pharmacother; 2017 Oct; 18(15):1595-1606. PubMed ID: 28847228
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Kuksa L; Barkane L; Hittel N; Gupta R
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29122917
    [No Abstract]   [Full Text] [Related]  

  • 73. Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
    Furin J; Brigden G; Lessem E; Rich M; Vaughan L; Lynch S
    Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26885674
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid.
    Lee HH; Jo KW; Yim JJ; Jeon D; Kang H; Shim TS
    Int J Infect Dis; 2020 Sep; 98():478-485. PubMed ID: 32640367
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
    Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
    Hewison C; Khan U; Bastard M; Lachenal N; Coutisson S; Osso E; Ahmed S; Khan P; Franke MF; Rich ML; Varaine F; Melikyan N; Seung KJ; Adenov M; Adnan S; Danielyan N; Islam S; Janmohamed A; Karakozian H; Kamene Kimenye M; Kirakosyan O; Kholikulov B; Krisnanda A; Kumsa A; Leblanc G; Lecca L; Nkuebe M; Mamsa S; Padayachee S; Thit P; Mitnick CD; Huerga H
    Clin Infect Dis; 2022 Sep; 75(6):1006-1013. PubMed ID: 35028659
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis.
    Shah I; Antony S; Jaiswal A; Bodhanwala M; Shah D; Tipre P; Salve J; Parmar M; Sachdeva KS
    Pediatr Infect Dis J; 2022 May; 41(5):401-404. PubMed ID: 35153288
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [EXPERIENCE OF USE OF NEW ANTI-TUBERCULOUS DRUG, DELAMANID IN MULTI- AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS CASES IN OUR HOSPITAL].
    Okumura M; Yoshiyama T
    Kekkaku; 2016 Nov; 91(11-12):699-702. PubMed ID: 30648372
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
    Sgaragli G; Frosini M; Saponara S; Corelli F
    Curr Med Chem; 2016; 23(21):2245-74. PubMed ID: 27142291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.